Rodrigo Cid
Family Health · Bullhead City, AZNPI 1306258116
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 141 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 22 manufacturers reported payments, led by AstraZeneca at 31.1% of the total. 2025 is the largest year on record at $759, 2.5 times the $305 reported in 2021.
Across 141 payments — averaging $20.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$876
- Lilly USA, LLC$483
- Xeris Pharmaceuticals, Inc.$197
- Amgen$180
- Dexcom, Inc.$168
- GSK$114
- plus $803 from 16 others
What the payments were for
- Food & beverage$2,821100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 36 | $876 |
| Lilly USA, LLC | 33 | $483 |
| Xeris Pharmaceuticals, Inc. | 10 | $197 |
| Amgen(2 entities) | 14 | $180 |
| Dexcom, Inc. | 9 | $168 |
| GSK | 6 | $114 |
| Boston Scientific | 1 | $114 |
| Novo Nordisk | 5 | $111 |
| Abbott | 4 | $74 |
| Pfizer | 4 | $69 |
| Sobi, Inc | 1 | $65 |
| Mimedx Group, Inc. | 1 | $61 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $60 |
| Exact Sciences | 3 | $56 |
| Astellas Pharma US Inc | 3 | $50 |
| Johnson & Johnson | 2 | $26 |
| Mannkind Corporation | 1 | $23 |
| Daiichi Sankyo Inc. | 1 | $23 |
| Corcept Therapeutics | 1 | $22 |
| Bayer | 1 | $19 |
| Sanofi-aventis U.S. LLC | 1 | $15 |
| Boehringer Ingelheim | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few family health providers in Arizonato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 171 | $206,664 |
| EliquisApixaban | 87 | $105,769 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 118 | $96,849 |
| JardianceEmpagliflozin | 63 | $81,491 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 97 | $74,216 |
| FarxigaDapagliflozin Propanediol | 67 | $61,050 |
| MounjaroTirzepatide | 38 | $56,030 |
| TrulicityDulaglutide | 56 | $55,131 |
| XareltoRivaroxaban | 29 | $44,352 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 42 | $44,311 |
| MyrbetriqMirabegron | 47 | $41,234 |
| JanuviaSitagliptin Phosphate | 31 | $40,335 |
| EntrestoSacubitril/Valsartan | 16 | $24,171 |
| Tresiba Flextouch U-200Insulin Degludec | 21 | $22,899 |
| LinzessLinaclotide | 25 | $19,405 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $111 | $206,664171 claims |
| AstraZenecaBreztri Aerosphere, Farxiga, Brilinta | $876 | $144,882178 claims |
| Lilly USA, LLCMounjaro, Trulicity | $483 | $111,16294 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta | $114 | $109,254152 claims |
| PfizerEliquis | $69 | $105,76987 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat | $14 | $87,09674 claims |
| Johnson & JohnsonXarelto | $26 | $44,35229 claims |
| Astellas Pharma US IncMyrbetriq | $50 | $41,23447 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few family health providers in Arizonaon file to place this against a meaningful peer group, so we don't.
Other family health in Bullhead City
- Larissa FloresPhoenix$3K
- Karen Runke PorcelloScottsdale$2K
- Cheryl ParkerTucson$1K
- Jennifer KernKingman$984
- Shawn SiqueirosTucson$510
- Sandra Barcelo-AdairSedona$276
- Jeff WaknitzSurprise$82
- Stewart LewisTucson$47
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.